NEW YORK (GenomeWeb) – Synthego — a Bay Area-based biotech startup aiming to automate and scale up genome engineering research — today announced it has raised $41 million in a Series B financing round.
AME Cloud Ventures, Elements Capital, OS Fund, Alexandria Equities, ZhenFund, and University of California, Berkeley CRISPR researcher Jennifer Doudna joined the round as new investors, which was led by venture capital firm 8VC. Existing investors Founders Fund, Menlo Ventures, WI Harper Group, and SciFi VC also participated.
Synthego said in a statement that it would use the funds to grow commercial operations, expand internationally, and introduce new products.
"Synthego has quickly emerged as a leading provider of synthetic RNA in the CRISPR market," 8VC Founding Partner Drew Oetting said in a statement.
The firm emerged from a four-year stealth period in August with synthetic guide RNAs for CRISPR applications. It raised $8.3 million in Series A financing and has closed several smaller private rounds.